Date: 2012-11-14
Type of information: R&D agreement
Compound: ModCell™ System
Company: GSK (UK) Alacris Theranostics (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: Based on genome and transcriptome information obtained by next generation sequencing and including kinetic pathway information, mutation and drug databases, this systems biology approach is providing a \"Virtual Patient\" model. The “Virtual Patient” model can predict the effect of drug treatment and optimized combinatory treatment providing means for cancer patient stratification and for personalized medicine approaches. In addition Alacris\' \"Virtual Clinical Trials\" system permits the in silico analysis of drugs, thus identifying specific patient groups or particular genetic profiles and diseases that could be targeted by the drug, with the goal of more efficient and precise treatment of patients.
Disease:
Details: Alacris Theranostics has entered into an agreement with GSK to apply Alacris\' proprietary ModCell™ System, developed at the Max Planck Institute for Molecular Genetics and licensed exclusively to Alacris, for drug stratification using data from early stage cancer drug discovery at GSK. GSK will provide to Alacris pre-clinical biology data from a drug discovery project in oncology. Alacris will exploit its proprietary Systems Biology model to determine the in silico effect of the inhibitor in its \"virtual clinical trial\" system. Alacris will then suggest which cancer cell lines as well as which cancers are more likely to respond to the inhibitor. This will be based on whole genome and transcriptome data that is integrated in the Alacris\' cancer model ModCell™.
Financial terms:
Latest news:
